MX2024007089A - Anticuerpos caninizados para el receptor alfa i de interleucina-31 canino. - Google Patents
Anticuerpos caninizados para el receptor alfa i de interleucina-31 canino.Info
- Publication number
- MX2024007089A MX2024007089A MX2024007089A MX2024007089A MX2024007089A MX 2024007089 A MX2024007089 A MX 2024007089A MX 2024007089 A MX2024007089 A MX 2024007089A MX 2024007089 A MX2024007089 A MX 2024007089A MX 2024007089 A MX2024007089 A MX 2024007089A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor alpha
- canine
- canine interleukin
- caninized antibodies
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163290259P | 2021-12-16 | 2021-12-16 | |
| US202163290256P | 2021-12-16 | 2021-12-16 | |
| US202263341443P | 2022-05-13 | 2022-05-13 | |
| PCT/EP2022/086084 WO2023111148A1 (en) | 2021-12-16 | 2022-12-15 | Caninized antibodies to canine interleukin-31 receptor alpha 1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007089A true MX2024007089A (es) | 2024-08-22 |
Family
ID=84923386
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007089A MX2024007089A (es) | 2021-12-16 | 2022-12-15 | Anticuerpos caninizados para el receptor alfa i de interleucina-31 canino. |
| MX2024007090A MX2024007090A (es) | 2021-12-16 | 2022-12-15 | Anticuerpos caninizados para el receptor alfa ii de interleucina-31 canino. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007090A MX2024007090A (es) | 2021-12-16 | 2022-12-15 | Anticuerpos caninizados para el receptor alfa ii de interleucina-31 canino. |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20250340653A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4448572A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2024546763A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2022409610A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3239826A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2024007089A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2023111128A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021335500A1 (en) | 2020-09-04 | 2023-05-04 | Elanco Us Inc. | Palatable formulations |
| US20250257142A1 (en) * | 2024-02-13 | 2025-08-14 | Invetx, Inc. | Anti-il-31ra antibodies and uses thereof |
| WO2026125320A1 (en) | 2024-12-10 | 2026-06-18 | Intervet International B.V. | Caninized il31rα antibodies with an extended half life |
| WO2026125322A1 (en) | 2024-12-10 | 2026-06-18 | Intervet International B.V. | CANINIZED IL31Rα ANTIBODIES WITH AN EXTENDED HALF LIFE |
| WO2026125321A1 (en) | 2024-12-10 | 2026-06-18 | Intervet International B.V. | Caninized il31rα antibodies with an extended half life |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
| US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
| US7696222B2 (en) | 2005-08-12 | 2010-04-13 | Merck Frosst Canada Ltd | Indole derivatives as CRTH2 receptor antagonists |
| RS53382B (sr) | 2008-08-20 | 2014-10-31 | Zoetis Llc | Jedinjenja pirol [2,3-d]pirimidina |
| WO2010031184A1 (en) | 2008-09-22 | 2010-03-25 | Merck Frosst Canada Ltd. | Azaindole derivatives as crth2 receptor antagonists |
| AU2009295229B2 (en) | 2008-09-22 | 2014-02-27 | Merck Canada Inc. | Indole derivatives as CRTH2 receptor antagonists |
| AU2010331927B2 (en) | 2009-12-17 | 2013-10-10 | Merck Canada Inc. | Aminopyrimidines as Syk inhibitors |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| AU2014368453B2 (en) | 2013-12-20 | 2020-04-16 | Intervet International B.V. | Caninized murine anti-canine PD-1 antibodies |
| EP3526246A1 (en) * | 2016-10-17 | 2019-08-21 | Vetoquinol SA | Modified antibody constant region |
| AU2017376398B2 (en) | 2016-12-14 | 2021-07-15 | Intervet International B.V. | Aminopyrazoles as selective janus kinase inhibitors |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| WO2020116560A1 (ja) * | 2018-12-05 | 2020-06-11 | 株式会社バイカ・セラピュティクス | 抗体のFc領域改変体 |
| CN120005022A (zh) * | 2019-01-03 | 2025-05-16 | 因外泰克斯公司 | 用于增加治疗剂在犬中的半衰期的组合物及使用方法 |
| CN110563844A (zh) * | 2019-09-04 | 2019-12-13 | 华中农业大学 | 一种抗犬白介素31受体的多克隆抗体及其应用 |
| WO2021123092A1 (en) * | 2019-12-20 | 2021-06-24 | Intervet International B.V. | Bispecific caninized antibodies for treating atopic dermatitis |
-
2022
- 2022-12-15 AU AU2022409610A patent/AU2022409610A1/en active Pending
- 2022-12-15 WO PCT/EP2022/086040 patent/WO2023111128A1/en not_active Ceased
- 2022-12-15 AU AU2022409603A patent/AU2022409603A1/en active Pending
- 2022-12-15 WO PCT/EP2022/086084 patent/WO2023111148A1/en not_active Ceased
- 2022-12-15 JP JP2024534474A patent/JP2024546763A/ja active Pending
- 2022-12-15 EP EP22840575.9A patent/EP4448572A1/en active Pending
- 2022-12-15 MX MX2024007089A patent/MX2024007089A/es unknown
- 2022-12-15 MX MX2024007090A patent/MX2024007090A/es unknown
- 2022-12-15 US US18/720,564 patent/US20250340653A1/en active Pending
- 2022-12-15 JP JP2024534465A patent/JP2024546759A/ja active Pending
- 2022-12-15 CA CA3239826A patent/CA3239826A1/en active Pending
- 2022-12-15 US US18/720,576 patent/US20250340654A1/en active Pending
- 2022-12-15 EP EP22840571.8A patent/EP4448571A1/en active Pending
- 2022-12-15 CA CA3239307A patent/CA3239307A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024007090A (es) | 2024-08-22 |
| AU2022409603A1 (en) | 2024-06-27 |
| WO2023111148A1 (en) | 2023-06-22 |
| US20250340653A1 (en) | 2025-11-06 |
| WO2023111128A1 (en) | 2023-06-22 |
| CA3239307A1 (en) | 2023-06-22 |
| US20250340654A1 (en) | 2025-11-06 |
| AU2022409610A1 (en) | 2024-05-30 |
| JP2024546763A (ja) | 2024-12-26 |
| CA3239826A1 (en) | 2023-06-22 |
| EP4448571A1 (en) | 2024-10-23 |
| EP4448572A1 (en) | 2024-10-23 |
| JP2024546759A (ja) | 2024-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024007090A (es) | Anticuerpos caninizados para el receptor alfa ii de interleucina-31 canino. | |
| MX2023004439A (es) | Anticuerpos caninizados contra el receptor alfa de la interleucina-31 canina. | |
| MX2023001727A (es) | Anticuerpos anti-c5 y usos de los mismos. | |
| MX2022007672A (es) | Anticuerpos del receptor alfa de interleucina-4 canina. | |
| PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
| EP3954710A3 (en) | Antibodies to canine interleukin-4 receptor alpha | |
| MY202336A (en) | Agonist antibodies that bind human cd137 and uses thereof | |
| MY205789A (en) | Anti-gdf15 antibodies, compositions and methods of use | |
| MX2023010499A (es) | Anticuerpos heterodimericos que se unen a cd3 y cldn6. | |
| MA40609B1 (fr) | Agents de liaison cd123 et leurs utilisations | |
| MX2022014995A (es) | Metodos de tratamiento de la nefropatia por iga con un anticuerpo de union a april. | |
| WO2020086406A3 (en) | Anti-npr1 antibodies and uses thereof | |
| SG10201804000TA (en) | Compositions for the treatment of rheumatoid arthritis and methods of using same | |
| EP4541807A3 (en) | Caninized human antibodies to human and canine il-4r alpha | |
| ZA201807816B (en) | Anti-il-22r antibodies | |
| MX2021013427A (es) | Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33. | |
| SG196839A1 (en) | Antibodies against fcrn and use thereof | |
| ZA202401100B (en) | Human interleukin-4 receptor alpha antibodies | |
| MX2024001954A (es) | Anticuerpos il-13 para el tratamiento de la dermatitis atopica. | |
| PH12019502617A1 (en) | Antibody-cytokine engrafted proteins and methods of use for immune related disorders | |
| MA43088A1 (fr) | Anticorps anti-il-17c | |
| MX2022016494A (es) | Anticuerpos anti-il13ra2. | |
| PH12020550340A1 (en) | Anti-pacap antibody | |
| WO2023172990A3 (en) | Epo receptor agonists and antagonists | |
| MX2025005092A (es) | Anticuerpo anti-trem2 y usos del mismo |